RxDoctor Payments Data

Maresa Lugo, MD

Neurology · Winter Haven, FLNPI 1477856631

Payments from drug & device makers

$34,482in general payments, 2019–2025

Across 815 payments — averaging $42.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$12K
  • AbbVie$8K
  • Amgen$1K
  • UCB, Inc.$971
  • EMD Serono, Inc.$884
  • Teva Pharmaceuticals USA, Inc.$707
  • plus $10K from 54 others

What the payments were for

  • Consulting fees$1,5254%
  • Speaking & faculty fees$15,41045%
  • Food & beverage$17,31350%
  • Education$2351%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer39$12,455
AbbVie(2 entities)182$7,968
Amgen(2 entities)45$1,003
UCB, Inc.37$971
EMD Serono, Inc.12$884
Teva Pharmaceuticals USA, Inc.29$707
AstraZeneca(2 entities)27$699
Lilly USA, LLC38$691
Eisai Inc.20$610
Argenx US, Inc.17$501
SK Life Science, Inc.18$463
Biohaven Pharmaceutical Holding Company Ltd.15$447
Sanofi20$446
Neurelis, Inc.23$442
Bristol Myers Squibb29$390
CSL Behring14$371
Biohaven Pharmaceuticals, Inc.10$332
Alnylam Pharmaceuticals Inc.12$328
Genentech USA, Inc.13$316
Novartis21$311
Sunovion Pharmaceuticals Inc.17$302
Biogen17$269
Johnson & Johnson(2 entities)14$258
Otsuka America Pharmaceutical, Inc.12$253
E.r. Squibb & Sons, L.L.C.5$240
Neurocrine Biosciences, Inc.8$233
Sumitomo Pharma America, Inc.11$216
Takeda Pharmaceuticals U.S.A., Inc.8$205
Axsome Therapeutics, Inc.9$196
Boston Scientific5$192
Acorda Therapeutics, Inc7$161
Acadia Pharmaceuticals Inc8$146
Merz Pharmaceuticals, LLC6$133
Jazz Pharmaceuticals Inc.5$124
Grifols USA, LLC6$107
Boehringer Ingelheim1$101
Tanabe Pharma America, Inc.4$87
Upsher-smith Laboratories LLC5$70
Lundbeck LLC3$65
Banner Life Sciences, LLC3$63
Supernus Pharmaceuticals, Inc.4$62
Scilex Pharmaceuticals Inc.3$59
Impel Pharmaceuticals Inc.3$58
Adamas Pharmaceuticals, Inc.3$51
Harmony Biosciences LLC3$50
Sanofi-aventis U.S. LLC2$50
Livanova USA, Inc.2$43
Corium, LLC2$38
C2n Diagnostics, LLC2$34
Impel Pharmaceuticals LLC2$28
Amneal Pharmaceuticals LLC2$28
Catalyst Pharmaceuticals, Inc.1$23
Silk Road Medical, Inc.1$23
Mallinckrodt Hospital Products Inc.1$23
Avanir Pharmaceuticals, Inc.1$21
Almatica Pharma LLC1$21
GRT US Holding, Inc.1$20
Abbott1$20
Zimmer Biomet1$19
Currax Pharmaceuticals LLC1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,482 in reported general payments places this provider in the 75th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$56,464
Medicare patients
232
Services billed
464

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammakedImmune Globul G/Gly/Iga Avg 4611$159,420
GilenyaFingolimod Hcl12$125,449
Nurtec OdtRimegepant Sulfate76$123,871
Aimovig AutoinjectorErenumab-Aooe72$73,812
UbrelvyUbrogepant42$68,552
QuliptaAtogepant42$61,791
Emgality PenGalcanezumab-Gnlm60$61,789
AptiomEslicarbazepine Acetate20$34,895
GlatopaGlatiramer Acetate12$32,256
BotoxOnabotulinumtoxina23$30,696
RexultiBrexpiprazole15$25,530
Lacosamide58$11,264
Teriflunomide25$5,390
Levetiracetam133$4,817
Carbidopa-LevodopaCarbidopa/Levodopa126$3,621

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Botox$7,968$161,039107 claims
NovartisGilenya$311$125,44912 claims
PfizerNurtec Odt, Dilantin$12,455$125,20094 claims
Sunovion Pharmaceuticals Inc.Aptiom$302$34,89520 claims
Otsuka America Pharmaceutical, Inc.Rexulti$253$25,53015 claims
Upsher-smith Laboratories LLCTopiramate$70$2,111115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,434 neurology providers in Florida.

Other neurology in Winter Haven

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →